The pre-seed round was backed by participants including Y Combinator and the UK government.
"The discovery of novel pharmaceuticals is one of our most important weapons in fighting disease. However, the drug development pipeline is often driven by trial-and-error and held up for many months during the identification of scalable manufacturing processes, delaying clinical trials. Our AI-powered models learn from historical data, cutting up to 95% of experimental work and accelerating these workflows by 30x."